Agios Pharmaceuticals (AGIO) risk factors, FY2024 10-K

Risks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates

1. 01If we do not successfully commercialize PYRUKYND® and other products for which we receive approval, our prospects may be substantially harmed
2. 02If we experience significant delays or an inability to successfully develop and commercialize PYRUKYND®, our business would be materially harmed
3. 03We may engage in in-licensing transactions or acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources
4. 04We or our collaborators may not be able to initiate, continue or complete clinical trials for our product candidates if we or they are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States
5. 05In addition, we have a small number of clinical trial sites for certain clinical trials in the Middle East, including in Lebanon and Israel, that could be affected by the current armed conflict in the region
6. 06Results of preclinical studies and early clinical trials may not be predictive of results of later-stage clinical trials
7. 07Interim and preliminary data from clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data
8. 08We conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense
9. 09We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
10. 10PYRUKYND®, or any of our product candidates that may receive marketing approval in the future, may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success
11. 11If we are unable to maintain sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing PYRUKYND® or any of our product candidates if they are approved
12. 12We may need to further build our sales and marketing infrastructure, either directly or with third-party partners to commercialize PYRUKYND® in other indications or outside of the United States, or to commercialize any of our other product candidates for which we obtain marketing approval
13. 13We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
14. 14If the FDA does not grant our products, if and when approved, appropriate periods of regulatory exclusivity before approving generic or follow-on versions of our products, the sales of our products could be adversely affected
15. 15seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States
16. 16Product liability lawsuits against us or any collaborators could cause us or our collaborators to incur substantial liabilities and could limit commercialization of any medicines that we or they may develop
17. 17Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur

Risks Related to Our Financial Position

1. 18We face challenges as a smaller, less diversified company
2. 19Raising additional capital may restrict our operations, require us to relinquish rights to our technologies or product candidates or cause dilution to our stockholders
3. 20If our existing capital is insufficient to fund our operating expenses and capital expenditures, we will need to raise capital, and if we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts
4. 21We have historically incurred operating losses. We expect to incur losses in the future and may never achieve or maintain profitability
5. 22Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition

Risks Related to Our Dependence on Third Parties

1. 23We rely and expect to continue to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing
2. 24If either we or any third parties on which we rely are adversely impacted by geopolitical events, rising global energy costs or energy shortages or rationing, delays may occur in our product development activities, which delays could have a material adverse impact on our business, financial condition and prospects
3. 25We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercialization
4. 26We may depend on collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates

Risks Related to Our Intellectual Property

1. 27We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful
2. 28Third parties may initiate legal proceedings alleging that we or our collaborators are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
3. 29We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
4. 30Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
5. 31If we are unable to protect the confidentiality of our confidential information related to our proprietary platforms and technology, our business and competitive position could be harmed
6. 32consider the confidential information and know-how related to our cellular metabolism technology platform to be our primary intellectual property assets in this space. Unpatented proprietary technical information and know-how can be difficult to protect

Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters

1. 33If we or our collaborators experience delays in obtaining approval or if we or they fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired
2. 34Failure to obtain marketing approval in foreign jurisdictions would prevent our medicines from being marketed in such jurisdictions and any of our medicines that are approved for marketing in such jurisdiction will be subject to risk associated with foreign operations
3. 35If a product candidate is intended for the treatment of a serious or life-threatening disease or condition and the product candidate demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for FDA fast track designation
4. 36We, or any collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our drug candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing drugs
5. 37PYRUKYND® or any product candidate that we commercialize may become subject to unfavorable pricing regulations and third-party reimbursement practices, which would harm our business
6. 38Current and future healthcare reform legislation may increase the difficulty and cost for us and any collaborators to obtain reimbursement and commercialize our drug candidates
7. 39The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States
8. 40healthcare products and services, which could result in reduced demand for our product or product candidates or additional pricing pressures
9. 41We are subject to U.S. and foreign export control, import, sanctions, anti-corruption and anti-money laundering laws with respect to our operations, and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business
10. 42With the passage of the CREATES Act, we are exposed to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications
11. 43court finds, by a preponderance of the evidence, that the NDA holder did not have a legitimate business justification to delay providing the product or failed to comply with the court’s order
12. 44If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

Risks Related to Employee Matters and Managing Growth

1. 45Our future success depends on our ability to retain our key executives and scientific leadership and to attract, retain and motivate qualified personnel
2. 46Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business

Risks Related to Our Common Stock and Other Matters

1. 47Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
2. 48The price of our common stock is likely to be volatile, which could result in substantial losses for purchasers of our common stock
3. 49Our executive officers, directors and principal stockholders maintain the ability to significantly influence all matters submitted to stockholders for approval
4. 50Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
5. 51did not have a qualified ownership change since our last review as of December 31, 2023. Future ownership changes under Section 382 may limit the amount of net operating loss and tax credit carryforwards that we could potentially utilize to reduce future tax liabilities
6. 52Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts
7. 53We incur costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices
8. 54Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders